Steve Biko Academic Hospital is the First in South Africa to Treat Liver Tumours with Sir-Spheres microspheres

Tuesday 01 May 2012
On Tuesday 24th April two South African patients were treated at Steve Biko Academic Hospital, Pretoria, with selective internal radiation therapy (SIRT) in the form of SIR-Spheres microspheres (yttrium-90 resin microspheres; Sirtex Medical Limited, Sydney, Australia) – an innovative form of internal radiotherapy for liver cancers. This form of liver radiotherapy has been shown to be effective in treating patients with different forms of inoperable liver tumours.

 

Over 5,000 patients are diagnosed with colorectal cancer in South Africa every year.1 In over 40% of colorectal cancer patients the disease will spread to their liver and cannot be removed surgically.2 In addition, around 3,500 South African patients are diagnosed with primary liver cancer every yearand approximately 85% of these will be inoperable.Patients with inoperable liver tumours often have a poor prognosis even when treated with modern systemic chemotherapy and/or biological agents. 

Professor Mike Sathekge, Head of Nuclear Medicine at Steve Biko Academic Hospital, Pretoria, said: “Selective Internal Radiation Therapy in the form of yttrium-90 resin microspheres is an exciting innovative radiation treatment for patients with inoperable liver tumours and we are very proud to be the first hospital in South Africa to introduce this form of treatment’’

Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumours. It is a minimally-invasive treatment, in which millions of radioactive microspheres (between 20-60 microns in diameter) are infused via a catheter into the liver, where they selectively target liver tumours with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue. There is a growing interest in SIRT using yttrium-90 resin microspheres for the treatment of patients with liver metastases or with primary liver cancer.  There is now substantial clinical evidence in comparative studies that SIRT in the form of SIR-Spheres microspheres are an effective and well tolerated therapy for treating patients with previously treated liver metastases from colorectal cancer. There is also mounting evidence that SIRT is an effective and well-tolerated treatment for inoperable primary liver cancer.

SIR-Spheres microspheres are approved for use in Australia, the European Union (CE Mark), Switzerland, Turkey and several other countries including in Asia (e.g. India, Korea, Singapore and Hong Kong) for the treatment of inoperable liver tumours.

SIR-Spheres microspheres are also full PMA-approved by the FDA and are indicated in the U.S. for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine.

A spokesperson from CANSA confirmed that the SIRT service recently launched at Steve Biko Academic Hospital for the treatment of patients with inoperable liver tumours was great news and would allow patients access to a novel therapy which has not routinely been available in South Africa until now.

References: 

  1. GLOBOCAN 2008. South African Republic estimated incidence of cancer (both sexes). http://globocan.iarc.fr/factsheet.asp#BOTH accessed 25th April 2012.
  2. Van Cutsem E, Nordlinger B, Cervantes A and On behalf of the ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol (2010) 21(suppl 5): v93-v97 doi:10.1093/annonc/mdq222.
  3. Pleguezuelo M, et al. Expert Rev Gastroenterol Hepatol 2008;2(6):761–84.

Steve Biko Academic Hospital contact details:

Department of Nuclear Medicine

Booking should strictly be done by your treating oncologist following consultation.

Patient Consent form

Tel: +27 12 354 1885/2374

Email: elmarie.wessels@up.ac.za


Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage